Exchange & Returns Information
Review Details
(28)
| Drug Type | Original |
|---|---|
| Active Ingredient | SEMAGLUTIDE |
| Strength | 0.5MG |
| Manufacturer | NOVO NORDISK |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 PEN | $ 360.00 | $ 360.00 |
$ 302.40
Apply WEGO26 (-16%)
You save $ 57.60
|
||
| 2 BOXES - 2 PENS | $ 299.50 |
17% $ 720.00
$ 599.00
|
$ 503.16
Apply WEGO26 (-16%)
You save $ 95.84
|
||
| ★ Best Value 3 BOXES - 3 PENS | $ 253.00 |
30% $ 1,080.00
$ 759.00
|
$ 637.56
Apply WEGO26 (-16%)
You save $ 121.44
|
Reference information will be available soon.
Wegovy 0.5mg Flextouch Pen is a prefilled once-weekly subcutaneous injection containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for long-term weight management in adults. By mimicking the endogenous hormone GLP-1, it enhances insulin secretion (when glucose is elevated), suppresses glucagon release, and delays gastric emptying, which collectively contribute to appetite reduction and improved metabolic regulation. Although semaglutide is also used off-label in type 2 diabetes care, Wegovy is formally indicated only for obesity treatment and must not be confused with diabetic therapies. Its once-weekly administration, non-stimulant profile, and robust clinical efficacy make it one of the most advanced anti-obesity drugs currently available.
- DIET (Metabolic Weight Control) > Wegovy is FDA-approved as a weight-loss medication for adults with obesity or overweight status who also present with at least one weight-related health issue. It reduces appetite, prolongs fullness after meals, and leads to sustainable fat loss when used alongside caloric restriction and exercise. - DIABETES (GLP-1 Receptor Agonists) > While semaglutide is a GLP-1 receptor agonist also prescribed off-label for blood glucose modulation, Wegovy itself does not carry an official indication for diabetes management. However, in certain clinical contexts, its use may indirectly assist in improving glycemic parameters in overweight patients, although such applications fall outside regulatory approval.
Semaglutide functions as a potent GLP-1 analog that binds to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. It enhances glucose-stimulated insulin release, inhibits glucagon secretion, and slows gastric emptying—mechanisms that reduce hunger signals and postprandial glucose spikes. In weight management, its primary benefit lies in altering central appetite pathways and digestive kinetics, promoting calorie deficit adherence without reliance on stimulants or appetite suppressants. Wegovy’s extended half-life allows for once-weekly administration, maintaining therapeutic effects consistently across 7 days.
→ Chronic Weight Management Dosing Protocol (Wegovy-specific): - Week 1–4: 0.25 mg SC once weekly - Week 5–8: 0.5 mg SC once weekly *(This product is used at this stage of titration)* - Week 9–12: 1.0 mg SC once weekly - Week 13–16: 1.7 mg SC once weekly - Maintenance (Week 17+): 2.4 mg SC once weekly → Dose Adjustments: - If gastrointestinal symptoms occur, delay dose escalation by 4 weeks - If 2.4 mg is not tolerated: reduce to 1.7 mg/week for a max of 4 weeks, then retry 2.4 mg - Discontinue therapy if 2.4 mg remains intolerable after repeated attempts → Eligibility Criteria: - Adults with BMI ≥30 kg/m² (obese) - Adults with BMI ≥27 kg/m² with at least one weight-related condition such as hypertension, dyslipidemia, or T2DM → Administration Notes: - Administer subcutaneously once per week, on the same day each week - May be injected into the abdomen, thigh, or upper arm - Rotate injection sites with each dose - Do not use in combination with other GLP-1 agonists or semaglutide products → Off-Label Use (Not Wegovy Indication): - For glycemic control: initiate at 0.25 mg/week SC, increase to 0.5–1.0 mg/week if tolerated - Often used in patients with type 2 diabetes and concurrent obesity - Caution: This application is not approved for Wegovy; use should be medically justified
Store refrigerated at 2–8°C before first use. Do not freeze. Keep in original packaging to protect from light. After first use, the pen may be stored at room temperature below 30°C for up to 28 days. Keep out of reach of children.
Common adverse effects include nausea, vomiting, diarrhea, constipation, abdominal cramping, and fatigue. These symptoms often emerge during dose escalation phases and usually subside within a few weeks. Less common but serious risks include pancreatitis, acute gallbladder disease, and kidney dysfunction, particularly in dehydrated individuals. Wegovy does not significantly increase hypoglycemia risk unless used in conjunction with insulin or sulfonylureas. Medical attention should be sought if persistent vomiting, severe abdominal pain, or signs of allergic reaction occur.
My second dose arrived right on time for me to continue my treatment without interruption.
Juggling work and family, the convenience of having my Wegovy prescription delivered is invaluable. This was my first time ordering the 0.5mg dose, and the process was seamless. The website remembered my details, making the reorder take seconds. The package arrived safely, and the medication was properly stored. This service saves me time and effort that I can now put towards my other health goals like meal prepping and exercise.
The cold-pack shipping is always perfect. It gives me confidence in the product's quality.
The website makes it incredibly easy to get your next month's dose. Very user-friendly.
For a medication you take weekly, consistency is everything. This is my second order, and the experience was identical to the first: easy, fast, and professional. The 0.5mg pen arrived in a perfectly chilled state, giving me confidence in its efficacy. Knowing that I don't have to worry about the logistics of getting my prescription each month allows me to focus completely on my health journey. That peace of mind is invaluable.
No combo deals available at the moment.
